New York-based investment adviser ARK Investment Management focused solely on “disruptive innovation” sees potential in AquaBounty.
In a financial filing, AquaBounty Technologies reports that ARK Investment Management has acquired 10.21 per-cent of shares in the biotechnology company for USD 2.7 million.
ARK Investment Management has invested in Spotify, Tesla, and Crispr Therapeutics.
Catherine Wood, CEO and CIO of ARK Invest, has previously spoken about how investors can take advantage of disruptive technologies in the genomic and biotech sectors. The company has stated that it aims to “provide exposure to DNA sequencing technology, gene editing, CRISPR, therapeutics, agricultural biology, and molecular diagnostics”.
AquaBounty Technologies is moving its first-ever commercial-scale harvest of genetically engineered-fast growing AquAdvantage salmon.
The fish was developed using transgenic methods to help it grow at a faster rate, from three years to 18 months.
